Literature DB >> 11215064

Metabolism of dauricine and identification of its main metabolites.

S Chen1, L Liu, Y Yang, Z Dai, F Zeng.   

Abstract

To study the metabolism of dauricine in vivo and in vitro and identify the structure of its main metabolites, urine of rats after drug administration as the samples of dauricine metabolism in vivo was studied. Rat liver S9 fraction was prepared and the oxygenation metabolism system reconstituted to perform phase I reaction of dauricine in vitro. TLC, HPLC-DAD and MS were used to analyze and identify dauricine and its main phase I metabolites in the samples. The results showed that besides the untransformed dauricine, in the urine samples there was little product of X' which had the same features of TLC, HPLC-DAD and MS as those of N-desmethyl dauricine (N-ddau). Part of dauricine could be transformed to a main metabolite X after incubating with S9 fraction in appropriate conditions. The molecular ion peak of X was m/z 611. The full scan MS2 spectrum of m/z 611 peak from S9 sample were m/z 580, m/z 566, m/z 552, m/z 206, which were same as those of N-ddau. Liver is the major organ for dauricine metabolism and part of dauricine is biotransformed by liver. The major metabolite is considered to be N-ddau.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11215064     DOI: 10.1007/bf02887006

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  5 in total

1.  A rapid in vitro method for the evaluation of potential antitumor drugs requiring metabolic activation by hepatic S9 enzymes.

Authors:  J Lebsanft; J B McMahon; G G Steinmann; R H Shoemaker
Journal:  Biochem Pharmacol       Date:  1989-12-15       Impact factor: 5.858

2.  Facile synthesis of [16,16,17-2H3]-testosterone, -epitestosterone and their glucuronides and sulfates.

Authors:  L D Bowers
Journal:  J Steroid Biochem Mol Biol       Date:  1996-05       Impact factor: 4.292

3.  In vivo and in vitro metabolism studies on a class III antiarrhythmic agent.

Authors:  S Vickers; C A Duncan; P H Kari; C F Homnick; J M Elliott; S M Pitzenberger; M Hichens; K P Vyas
Journal:  Drug Metab Dispos       Date:  1993 May-Jun       Impact factor: 3.922

4.  The interaction of omeprazole with rat liver cytochrome P450-mediated monooxygenase reactions in vitro and in vivo.

Authors:  R J Chenery; A Ayrton; H G Oldham; S J Norman; P Standring
Journal:  Biochem Pharmacol       Date:  1988-04-01       Impact factor: 5.858

5.  Biotransformation of the platinum drug JM216 following oral administration to cancer patients.

Authors:  F I Raynaud; P Mistry; A Donaghue; G K Poon; L R Kelland; C F Barnard; B A Murrer; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

  5 in total
  2 in total

1.  Identification of three new N-demethylated and O-demethylated bisbenzylisoquinoline alkaloid metabolites of isoliensinine from dog hepatic microsomes.

Authors:  Hui Zhou; Liping Li; Huidi Jiang; Su Zeng
Journal:  Molecules       Date:  2012-10-01       Impact factor: 4.411

2.  Dauricine suppresses the growth of pancreatic cancer in vivo by modulating the Hedgehog signaling pathway.

Authors:  Ying-Bo Zhang; Hong-Xin Fei; Jia Guo; Xiao-Jie Zhang; Shu-Liang Wu; Li-Li Zhong
Journal:  Oncol Lett       Date:  2019-09-03       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.